Teva Pharmaceutical Industries Achieves Investment-Grade Ratings and Outlines Growth Strategy
Teva Pharmaceutical Industries (NYSE:TEVA) has secured investment-grade credit ratings from all three major agencies, a year ahead of schedule. This achievement is attributed to debt reduction efforts and positive expectations for future EBITDA growth. The company anticipates refinancing will reduce financing expenses by around $400 million in the coming year, offering greater financial flexibility. Teva plans to focus business development on innovative medicines within neurology, immunology, and rare diseases while expanding its generics and biosimilars portfolio. CEO Richard Francis emphasized a disciplined approach to investments and pricing as Teva shifts from debt reduction toward growth initiatives. The company aims to launch five new products over the next five years. Teva's U.S. generics business is expected to remain stable or slightly grow in 2026, reversing earlier projections of decline. Pipeline programs include treatments for celiac disease and vitiligo as well as long-acting olanzapine and ecopipam.
Tickers: $TEVA
Topics: business development debt reduction EBITDA growth investment-grade ratings